2. Induced Disease Models Products Others Apoptosis
  3. Cancer Models Skin Disease Models Reproductive System Disease Models Environmental Pollutants c-Myc
  4. Skin Cancer Models
  5. DMBA

DMBA  (Synonyms: 7,12-DMBA; 7,12-Dimethylbenzanthracene)

Art. -Nr.: HY-W011845 Reinheit: 99.94%
COA
SDS
Handling Instructions Technical Support

DMBA has carcinogenic activity as a polycyclic aromatic hydrocarbon (PAH). DMBA is used to induce tumor formation in various rodent models.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr. : 57-97-6

Größe Preis Verfügbarkeit Menge
Kostenlose Probe (0.1 - 0.2 mg)   Jetzt bewerben  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 Auf Lager
Solution
10 mM * 1 mL in DMSO Auf Lager
Solid
25 mg Auf Lager
50 mg Auf Lager
100 mg Auf Lager
250 mg Auf Lager
1 g Auf Lager
5 g   Angebot einholen  
10 g   Angebot einholen  

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Kundenbewertung

Based on 3 publication(s) in Google Scholar

Other Forms of DMBA:

DMBA Related Antibodies

Top Publications Citing Use of Products

    DMBA purchased from MedChemExpress. Usage Cited in: Sci China Life Sci. 2026 May;69(5):1604-1619.  [Abstract]

    Representative images and tumor size of DMBA (75 ug; topical application; twice a week)-induced melanoma in Mat2a+/+ and Mat2a-/- mice (n=6 per group). Scale bar, 1 cm.

    DMBA purchased from MedChemExpress. Usage Cited in: J Invest Dermatol. 2025 Nov 4:S0022-202X(25)03517-1.  [Abstract]

    Tumor burden of WT mice and MC-deficient KITW-sh/W-sh mice 28 weeks into the DMBA (25 µg DMBA dissolved in 200 µL acetone; topical application)/TPA protocol.

    DMBA purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Sep 9;242(Pt 2):117322.  [Abstract]

    Representative pancreatic HE staining and pancreatic tissue of WT and Reg3g−/− mice induced by DMBA (Orthotopic Implantation) for 82 days.

    DMBA purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Sep 9;242(Pt 2):117322.  [Abstract]

    Representative pancreatic CK19 immunofluorescence staining of WT and Reg3g−/− mice induced by DMBA (Orthotopic Implantation) for 82 days.

    DMBA purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Sep 9;242(Pt 2):117322.  [Abstract]

    Representative liver Ki67 IHC staining of WT and Reg3g−/− mice induced by DMBA (Orthotopic Implantation) for 82 days.

    • Biologische Aktivität

    • Reinheit & Dokumentation

    • Verweise

    • Kundenbewertung

    Beschreibung

    DMBA has carcinogenic activity as a polycyclic aromatic hydrocarbon (PAH). DMBA is used to induce tumor formation in various rodent models[1].

    In Vivo

    Note:
    Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

    DMBA can induce breast cancer and skin cancer models. Oral administration of DMBA (0-150 mg/kg) leads to a reduction in spleen weight and a decrease in the total number of lymphocytes recovered from the spleen in C57BL/6 mice. In SD rats, DMBA exhibits a terminal deposition half-life of 45 minutes across all dose ranges (5-50 mg)[5].

    Induction of breast cancer[2]
    Background
    DMBA activates AhR, which translocates into nucleus and dimerizes with cofactor ARNT, thus induces the expressions of protooncogenes c-myc.
    Specific Modeling Methods
    Rat: Sprague-Dawley • female • 50 days •140-150 g
    Administration: 15-20 mg DMBA-• intragastric gavage • single dose
    Note
    1.5-2 g DMBA dissolved in 100 ml sesame oil
    Modeling Indicators
    Palpation:Detection of mammary cancer in 150 days.
    Histology analysis:The tumor exhibits tightly spaced chords epithelial cells, cysts and papillary structures.
    Phenotype:develops a temporary cessation in body growth.
    Opposite Product(s): Phytic acid (HY-N0814); Limonene (HY-N0544)

    Induction of skin cancer[3]
    Background
    DMBA is metabolized to reactive intermediates, such as syn- and anti-diol epoxides, and binds extensively to epidermal DNA.
    Specific Modeling Methods
    European hamster: • 10 weeks • 180-200 g •
    Administration: 25 mg DMBA • applied on the shaved back skin • single dose
    Note
    25 mg DMBA is dissolved in 1 ml acetone
    Modeling Indicators
    Histological analysis: Epidermal hyperplasia is oberserved. Lesions occurred frequently in the back skin, such as trichoepitheliomas, neoplastic epidermal cysts and melanotic tumors.
    Opposite Product(s): α-Mangostin (HY-N0328); DHEA (HY-14650); Salidroside (HY-N0109)

    Induction of lung cancer[4]
    Background
    DMBA is metabolized by cytochrome P450 enzymes into the carcinogenic form 7,12-DMBA-3,4-dihydrodiol-1,2- epoxide, which adducts with DNA and produces mutations.
    Specific Modeling Methods
    BALB/c mice: •12 weeks • 25-35 g
    Administration: 5-20 mg/kg • intratracheal instillation • single dose.
    Note
    (1). 5-20 mg DMBA is dissolved in 0.2 ml saline.
    (2). A coat of antibiotic is applied after the instillation.
    Modeling Indicators
    Molecular changes:Increased number of macrophages in the broncho-alveolar lavage (BAL) fluid and levels of malonyldialdehyde (MDA) in lung tissue.
    Histology analysis:Inflammation with alveolar epithelial hyperplasia, adenic metaplasia, adenomatoid hyperplasia and atypical hyperplasia.
    Opposite Product(s): Diclofenac (HY-15036)

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Molekulargewicht

    256.35

    Formel

    C20H16
    CAS. Nr.
    Appearance

    Solid

    Color

    White to off-white

    SMILES

    CC(C1=CC=CC=C21)=C3C=CC4=CC=CC=C4C3=C2C
    Versand

    Room temperature in continental US; may vary elsewhere.
    Speicherung
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Lösungsmittel & Löslichkeit
    In Vitro: 

    Acetone : 25 mg/mL (97.52 mM; Need ultrasonic)

    DMSO : ≥ 12.5 mg/mL (48.76 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Ethanol : 3.33 mg/mL (12.99 mM; ultrasonic and warming and heat to 60°C)

    *"≥" means soluble, but saturation unknown.

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.9009 mL 19.5046 mL 39.0092 mL
    5 mM 0.7802 mL 3.9009 mL 7.8018 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molaritätsrechner

    • Verdünnungsrechner

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 2.5 mg/mL (9.75 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2 mg/mL (7.80 mM); Clear solution

      This protocol yields a clear solution of ≥ 2 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  Corn Oil

      Solubility: 20 mg/mL (78.02 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Reinheit & Dokumentation

    Purity: 99.94%

    SDS (644 KB)

    COA (251 KB) HNMR (245 KB) RP-HPLC (255 KB) MS (72 KB)

    Handling Instructions (2659 KB)
    Verweise

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    Ethanol / DMSO / Acetone 1 mM 3.9009 mL 19.5046 mL 39.0092 mL 97.5229 mL
    5 mM 0.7802 mL 3.9009 mL 7.8018 mL 19.5046 mL
    10 mM 0.3901 mL 1.9505 mL 3.9009 mL 9.7523 mL
    DMSO / Acetone 15 mM 0.2601 mL 1.3003 mL 2.6006 mL 6.5015 mL
    20 mM 0.1950 mL 0.9752 mL 1.9505 mL 4.8761 mL
    25 mM 0.1560 mL 0.7802 mL 1.5604 mL 3.9009 mL
    30 mM 0.1300 mL 0.6502 mL 1.3003 mL 3.2508 mL
    40 mM 0.0975 mL 0.4876 mL 0.9752 mL 2.4381 mL
    Acetone 50 mM 0.0780 mL 0.3901 mL 0.7802 mL 1.9505 mL
    60 mM 0.0650 mL 0.3251 mL 0.6502 mL 1.6254 mL
    80 mM 0.0488 mL 0.2438 mL 0.4876 mL 1.2190 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    DMBA Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    DMBA57-97-67,12-DMBA 7,12-DimethylbenzanthraceneEnvironmental Pollutantsc-MycEnvironmental ContaminantsMycInhibitorinhibitorinhibit

    Ihre kürzlich angesehenen Produkte:

    Online-Anfrage

    Your information is safe with us. * Required Fields.

    Produktname

    		  

    Requested Quantity *

    Name des Antragstellers *

    		 

    Anrede

    E-Mail-Addresse *

    		 

    Telefonnummer *

    Department

    		 

    Name der Organisation *

    City

    Bundesland

    Country or Region *

    		      

    Bemerkungen

    Massenanfrage

    Inquiry Information

    Produktname:
    DMBA
    Art. -Nr.:
    HY-W011845
    Menge:
    MCE Japan Authorized Agent:

    Kundenbewertung

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Produktname

    		  

    Lot #

    Name des Antragstellers *

    		 

    E-Mail-Addresse *

    Telefonnummer

    		 

    Department *

    Name der Organisation *

    		 

    Country or Region *

    Bemerkungen

    SAFETY DATA SHEET (SDS)

    English - EN (644 KB) Français - FR (644 KB) Deutsch - DE (644 KB) Norwegian - NO (644 KB) Español - ES (644 KB) Swedish - SV (644 KB) Italian - IT (644 KB) Korean - KR (644 KB) Portuguese - PT (644 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.